Related Experiment Video
Updated: Jul 14, 2026

Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
The argument for conservative, delayed surgery in the management of prostatic rhabdomyosarcoma
T E Lobe1, E Wiener, R J Andrassy
1Intergroup Rhabdomyosarcoma Study (IRS) Group, Omaha, Nebraska, USA.
Abstract:
Exenteration is no longer required for most patients who have rhabdomyosarcoma (RMS) of the prostate. This site comprised only about 5% of newly diagnosed cases in the IRS-III (1984-1991). The mean age at the time of diagnosis was 5.3 yrs (range, 0 to 19 years). Most tumors were relatively large, had embryonal histology, and were clinically localized but unresectable without major loss of organ function. The 44 patients with group III tumors (gross residual disease) were treated according to the IRS-III protocol. Forty-three of them underwent biopsy only, and one patient had subtotal resection as the initial procedure. The average number of surgical procedures per patient was two (range, one to five). Six of the 44 patients had no additional surgery. The second-look procedures performed in the other 38 patients included exenteration (14), prostatectomy (7), cystoscopic/perineal needle biopsy (8), laparotomy with biopsy (6), and subtotal excision with bladder salvage (3). Additional surgery was required for four patients, for evaluation of a residual mass, postoperative fistula, ureteral stricture, or small bowel obstruction. Six patients with relapse or residual disease underwent additional chemotherapy and late exenteration (3), prostatectomy (1), or biopsy (2). Four of the six have been cured, one is in treatment for a second malignancy, and the other has residual disease after exenteration. Thirty-six of the 44 patients with group III tumors have been cured (minimum follow-up period, 6 years; range, 6 to 11 years), compared with 23 of the 47 in IRS-II (1978-1984) (P = .001). Two of the six deaths in this group were caused by infection. The bladder salvage rate for those cured of their disease also was better (64% v 57% for IRS-II). The two patients with group IIA tumors were cured by gross primary excision, local radiotherapy, and vincristine and actinomycin therapy. By contrast, all patients with metastatic disease (group IV) died of the tumor. Conservative, delayed surgery, performed after intensive chemotherapy with or without radiotherapy, yields a better cure rate while maintaining a high rate of bladder salvage in children with group III prostatic RMS.
Insights
Radical surgery like exenteration is often unnecessary for pediatric prostate rhabdomyosarcoma (RMS). Intensive chemotherapy and delayed, conservative surgery improve cure rates and preserve bladder function in localized disease.
Area of Science:
- Pediatric Oncology
- Surgical Oncology
- Radiation Oncology
Background:
- Prostate rhabdomyosarcoma (RMS) is a rare pediatric malignancy.
- Historically, radical surgery including exenteration was standard for localized disease.
- Treatment protocols have evolved to improve outcomes and organ preservation.
Purpose of the Study:
- To evaluate the efficacy of conservative, delayed surgical approaches for localized prostate rhabdomyosarcoma.
- To compare outcomes of the IRS-III protocol with the previous IRS-II protocol.
- To assess bladder salvage rates in patients treated with modern protocols.
Main Methods:
- Retrospective analysis of 44 patients with group III (gross residual disease) prostate RMS treated under the IRS-III protocol.
- Comparison with 47 patients from the IRS-II protocol.
- Detailed review of surgical procedures, including biopsy, subtotal resection, and second-look surgeries.
- Analysis of chemotherapy and radiotherapy regimens.
Main Results:
- The cure rate for group III prostate RMS significantly improved from 49% in IRS-II to 82% in IRS-III (36/44 patients).
- Bladder salvage rates were higher in IRS-III (64%) compared to IRS-II (57%).
- Conservative management with delayed surgery after chemotherapy yielded better outcomes than historical radical approaches.
Conclusions:
- Exenteration is no longer the standard of care for most localized prostate rhabdomyosarcoma.
- Intensive chemotherapy followed by conservative, delayed surgery offers superior cure rates and bladder preservation.
- Metastatic disease (group IV) remains associated with a poor prognosis.

